Astragaloside IV inhibits pathological functions of gastric cancer-associated fibroblasts through regulation of the HOXA6/ZBTB12 axis

1H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. 71(3) (2021) 209–249; https://doi.org/10.3322/caac.21660Search in Google Scholar

2Y. Zeng and R. U. Jin, Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer, Semin. Cancer Biol. 86(3) (2022) 566–582; https://doi.org/10.1016/j.semcancer.2021.12.004Search in Google Scholar

3E. C. Smyth, M. Nilsson, H. I. Grabsch, N. C. van Grieken and F. Lordick, Gastric cancer, Lancet 396 (2020) 635–648; https://doi.org/10.1016/s0140-6736(20)31288-5Search in Google Scholar

4S. S. Joshi and B. D. Badgwell, Current treatment and recent progress in gastric cancer, CA Cancer J. Clin. 71(3) (2021) 264–279; https://doi.org/10.3322/caac.21657Search in Google Scholar

5Y. Xiao and D. Yu, Tumor microenvironment as a therapeutic target in cancer, Pharmacol. Ther. 221 (2021) Article ID 107753 (30 pages); https://doi.org/10.1016/j.pharmthera.2020.107753Search in Google Scholar

6T. A. Karakasheva, E. W. Lin, Q. Tang, E. Qiao, T. J. Waldron, M. Soni, A. J. Klein-Szanto, V. Sahu, D. Basu, S. Ohashi, K. Baba, Z. T. Giaccone, S. R. Walker, D. A. Frank, E. P. Wileyto, Q. Long, M. C. Dunagin, A. Raj, J. A. Diehl, K. K. Wong, A. J. Bass and A. K. Rustgi, IL-6 mediates cross-talk between tumor cells and activated fibroblasts in the tumor microenvironment, Cancer Res. 78(17) (2018) 4957–4970; https://doi.org/10.1158/0008-5472.can-17-2268Search in Google Scholar

7H. Sun, X. Wang, X. Wang, M. Xu and W. Sheng, The role of cancer-associated fibroblasts in tumorigenesis of gastric cancer, Cell Death Dis. 13 (2022) Article ID 874 (9 pages); https://doi.org/10.1038/s41419-022-05320-8Search in Google Scholar

8H. Zhang, T. Deng, R. Liu, T. Ning, H. Yang, D. Liu, Q. Zhang, D. Lin, S. Ge, M. Bai, X. Wang, L. Zhang, H. Li, Y. Yang, Z. Ji, H. Wang, G. Ying and Y. Ba, CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer, Mol. Cancer 19 (2020) Article ID 43 (17 pages); https://doi.org/10.1186/s12943-020-01168-8Search in Google Scholar

9X. Liu, L. Yao, J. Qu, L. Liu, N. Lu, J. Wang and J. Zhang, Cancer-associated fibroblast infiltration in gastric cancer: the discrepancy in subtypes pathways and immunosuppression, J. Transl. Med. 19 (2021) Article ID 325 (16 pages); https://doi.org/10.1186/s12967-021-03012-zSearch in Google Scholar

10G. Itoh, K. Takagane, Y. Fukushi, S. Kuriyama, M. Umakoshi, A. Goto, K. Yanagihara, M. Yashiro and M. Tanaka, Cancer-associated fibroblasts educate normal fibroblasts to facilitate cancer cell spreading and T-cell suppression, Mol. Oncol. 16(1) (2022) 166–187; https://doi.org/10.1002/1878-0261.13077Search in Google Scholar

11Y. Yan, L. F. Wang and R. F. Wang, Role of cancer-associated fibroblasts in invasion and metastasis of gastric cancer, World J. Gastroenterol. 21(33) (2015) 9717–9726; https://doi.org/10.3748/wjg.v21.i33.9717Search in Google Scholar

12J. Zheng, M. Wu, H. Wang, S. Li, X. Wang, Y. Li, D. Wang and S. Li, Network pharmacology to unveil the biological basis of health-strengthening herbal medicine in cancer treatment, Cancers (Basel) 10(46) (2018) Article ID 461 (23 pages); https://doi.org/10.3390/cancers10110461Search in Google Scholar

13J. Liu, S. Wang, Y. Zhang, H. T. Fan and H. S. Lin, Traditional Chinese medicine and cancer: History, present situation, and development, Thorac. Cancer 6(5) (2015) 561–569; https://doi.org/10.1111/1759-7714.12270Search in Google Scholar

14J. Zhang, J. Gao, J. Cui, Y. Wang, Y. Jin, D. Zhang, D. Lin and J. Lin, Tumor-associated macrophages in tumor progression and the role of traditional Chinese medicine in regulating TAMs to enhance antitumor effects, Front. Immunol. 13 (2022) Article ID 1026898 (10 pages); https://doi.org/10.3389/fimmu.2022.1026898Search in Google Scholar

15Y. Luo, S. Yin, J. Lu, S. Zhou, Y. Shao, X. Bao, T. Wang, Y. Qiu and H. Yu, Tumor microenvironment: a prospective target of natural alkaloids for cancer treatment, Cancer Cell Int. 21 (2021) Article ID 386 (20 pages); https://doi.org/10.1186/s12935-021-02085-6Search in Google Scholar

16Y. Zhang, Y. Lou, J. Wang, C. Yu and W. Shen, Research status and molecular mechanism of the traditional Chinese medicine and antitumor therapy combined strategy based on tumor microenvironment, Front. Immunol. 11 (2020) Article ID 609705 (13 pages); https://doi.org/10.3389/fimmu.2020.609705Search in Google Scholar

17F. Xu, W. Q. Cui, Y. Wei, J. Cui, J. Qiu, L. L. Hu, W. Y. Gong, J. C. Dong and B. J. Liu, Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling, J. Exp. Clin. Cancer Res. 37 (2018) Article ID 207 (16 pages); https://doi.org/10.1186/s13046-018-0878-0Search in Google Scholar

18T. Chen, P. Yang and Y. Jia, Molecular mechanisms of astragaloside-IV in cancer therapy, Int. J. Mol. Med. 47 (2021) Article ID 13 (13 pages); https://doi.org/10.3892/ijmm.2021.4846Search in Google Scholar

19Z. Jiang and Z. Mao, Astragaloside IV (AS-IV) alleviates the malignant biological behavior of hepatocellular carcinoma via Wnt/β-catenin signaling pathway, RSC Adv. 9(61) (2019) 35473–35482; https://doi.org/10.1039/c9ra05933dSearch in Google Scholar

20D. Xia, W. Li, C. Tang and J. Jiang, Astragaloside IV, as a potential anticancer agent, Front. Pharmacol. 14 (2023) Article ID 1065505 (15 pages); https://doi.org/10.3389/fphar.2023.1065505Search in Google Scholar

21T. Cai, C. Zhang, Z. Zhao, S. Li, H. Cai, X. Chen, D. Cai, W. Liu, Y. Yan, K. Xie, H. Pan and X. Zeng, The gastric mucosal protective effects of astragaloside IV in mnng-induced GPL rats, Biomed. Pharma cother. 104 (2018) 291–299; https://doi.org/10.1016/j.biopha.2018.04.013Search in Google Scholar

22F. Li, K. Cao, M. Wang, Y. Liu and Y. Zhang, Astragaloside IV exhibits anti-tumor function in gastric cancer via targeting circRNA dihydrolipoamide S-succinyltransferase (circDLST)/miR-489-3p/euka ryotic translation initiation factor 4A1(EIF4A1) pathway, Bioengineered 13(4) (2022) 10111–10122; https://doi.org/10.1080/21655979.2022.2063664Search in Google Scholar

23Z. F. Wang, D. G. Ma, Z. Zhu, Y. P. Mu, Y. Y. Yang, L. Feng, H. Yang, J. Q. Liang, Y. Y. Liu, L. Liu and H. W. Lu, Astragaloside IV inhibits pathological functions of gastric cancer-associated fibroblasts, World J. Gastroenterol. 23(48) (2017) 8512–8525; https://doi.org/10.3748/wjg.v23.i48.8512Search in Google Scholar

24J. Lin, H. Zhu, L. Hong, W. Tang, J. Wang, H. Hu, X. Wu, Y. Chen, G. Liu, Q. Yang, J. Li, Y. Wang, Z. Lin, Y. Xiao, W. Dai, M. Huang, G. Li, A. Li, J. Wang, L. Xiang and S. Liu, Coexpression of HOXA6 and PBX2 promotes metastasis in gastric cancer, Aging (Albany NY) 13(5) (2021) 6606–6624; https://doi.org/10.18632/aging.202426Search in Google Scholar

25G. Biffi and D. A. Tuveson, Diversity and biology of cancer-associated fibroblasts, Physiol. Rev. 101(1) (2021) 147–176; https://doi.org/10.1152/physrev.00048.2019Search in Google Scholar

26X. Chen and E. Song, Turning foes to friends: targeting cancer-associated fibroblasts, Nat. Rev. Drug Discov. 18 (2019) 99–115; https://doi.org/10.1038/s41573-018-0004-1Search in Google Scholar

27Y. Miyai, N. Esaki, M. Takahashi and A. Enomoto, Cancer-associated fibroblasts that restrain cancer progression: Hypotheses and perspectives, Cancer Sci. 111(4) (2020) 1047–1057; https://doi.org/10.1111/cas.14346Search in Google Scholar

28B. C. Özdemir, T. Pentcheva-Hoang, J. L. Carstens, X. Zheng, C. C. Wu, T. R. Simpson, H. Laklai, H. Sugimoto, C. Kahlert, S. V. Novitskiy, A. De Jesus-Acosta, P. Sharma, P. Heidari, U. Mahmood, L. Chin, H. L. Moses, V. M. Weaver, A. Maitra, J. P. Allison, V. S. LeBleu and R. Kalluri, Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival, Cancer Cell. 25(6) (2014) 719–734; https://doi.org/10.1016/j.ccr.2014.04.005Search in Google Scholar

29H. Kobayashi, A. Enomoto, S. L. Woods, A. D. Burt, M. Takahashi and D. L. Worthley, Cancer-associated fibroblasts in gastrointestinal cancer, Nat. Rev. Gastroenterol. Hepatol. 16 (2019) 282–295; https://doi.org/10.1038/s41575-019-0115-0Search in Google Scholar

30Y. Lu, Z. Jin, J. Hou, X. Wu, Z. Yu, L. Yao, T. Pan, X. Chang, B. Yu, J. Li, C. Li, M. Yan, C. Yan, Z. Zhu, B. Liu and L. Su, Calponin 1 increases cancer-associated fibroblasts-mediated matrix stiffness to promote chemoresistance in gastric cancer, Matrix Biol. 115 (2023) 1–15; https://doi.org/10.1016/j.matbio.2022.11.005Search in Google Scholar

31C. Zhang, L. Li, S. Hou, Z. Shi, W. Xu, Q. Wang, Y. He, Y. Gong, Z. Fang and Y. Yang, Astragaloside IV inhibits hepatocellular carcinoma by continually suppressing the development of fibrosis and regulating pSmad3C/3L and Nrf2/HO-1 pathways, J. Ethnopharmacol. 279(28) (2021) Article ID 114350 (13 pages); https://doi.org/10.1016/j.jep.2021.114350Search in Google Scholar

32S. Wang, J. Mou, L. Cui, X. Wang and Z. Zhang, Astragaloside IV inhibits cell proliferation of colorectal cancer cell lines through down-regulation of B7-H3, Biomed. Pharmacother. 102 (2018) 1037–1044; https://doi.org/10.1016/j.biopha.2018.03.127Search in Google Scholar

33K. Jiang, Q. Lu, Q. Li, Y. Ji, W. Chen and X. Xue, Astragaloside IV inhibits breast cancer cell invasion by suppressing Vav3 mediated Rac1/MAPK signaling, Int. Immunopharmacol. 42 (2017) 195–202; https://doi.org/10.1016/j.intimp.2016.10.001Search in Google Scholar

34J. Zhu and K. Wen, Astragaloside IV inhibits TGF-β1-induced epithelial-mesenchymal transition through inhibition of the PI3K/Akt/NF-κB pathway in gastric cancer cells, Phytother. Res. 32(7) (2018) 1289–1296; https://doi.org/10.1002/ptr.6057Search in Google Scholar

35J. Xiulin, C. Wang, J. Guo, C. Wang, C. Pan and Z. Nie, Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma, Aging (Albany NY) 14(6) (2022) 2819–2854; https://doi.org/10.18632/aging.203977Search in Google Scholar

36F. Wu, S. Wu, H. Tong, W. He and X. Gou, HOXA6 inhibits cell proliferation and induces apoptosis by suppressing the PI3K/Akt signaling pathway in clear cell renal cell carcinoma, Int. J. Oncol. 54(6) (2019) 2095–2105; https://doi.org/10.3892/ijo.2019.4789Search in Google Scholar

37S. Wu, F. Wu and Z. Jiang, Effect of HOXA6 on the proliferation, apoptosis, migration and invasion of colorectal cancer cells, Int. J. Oncol. 52(6) (2018) 2093–2100; https://doi.org/10.3892/ijo.2018.4352Search in Google Scholar

38D. Han, G. Liu, Y. Oh, S. Oh, S. Yang, L. Mandjikian, N. Rani, M. C. Almeida, K. S. Kosik and J. Jang, ZBTB12 is a molecular barrier to dedifferentiation in human pluripotent stem cells, Nat. Commun. 14 (2023) Article ID 632 (16 pages); https://doi.org/10.1038/s41467-023-36178-9Search in Google Scholar

39Q. Pan, Y. Ning, L. Z. Chen, S. Zhang, Z. Z. Liu, X. X. Yang, W. Wei, H. Wei, Q. G. Li, H. N. Yue and J. X. Wang, Association of MHC class-III gene polymorphisms with ER-positive breast cancer in Chinese Han population, Genet. Mol. Res. 11(4) (2012) 4299–4306; https://doi.org/10.4238/2012.September.17.1Search in Google Scholar

40S. Bhatlekar, J. Z. Fields and B. M. Boman, HOX genes and their role in the development of human cancers, J. Mol. Med. 92 (2014) 811–823; https://doi.org/10.1007/s00109-014-1181-ySearch in Google Scholar